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Abstract: Treatment-Resistant Depression (TRD) represents a source of ongoing clinical and nosological controversy and 
confusion. While no univocal consensus on its definition and specific correlation with major mood disorders has been 
reached to date, a progressively greater number of evidences tend to suggest a revision of current clinical nosology. Since 
a better assessment of TRD should be considered mandatory in order to achieve the most appropriate clinical manage-
ment, this narrative review aims to briefly present current most accepted definitions of the phenomenon, speculating on its 
putative bipolar diathesis for some of the cases originally assessed as unipolar depression. 
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EPIDEMIOLOGY OF TRD 
Treatment-resistant depression (TRD) is a relatively 
common condition presenting with substantial challenges to 
both the clinician and researcher [1]. 
In fact, despite a progressively higher number of avail-
able antidepressant therapies, TRD occurs frequently in 
clinical practice, and is associated with profound psychoso-
cial disability, personal suffering and economic cost burden.  
Between one and two thirds of Major Depressive Disorder 
(MDD) patients will not respond to the first antidepressant 
prescribed and 15 to 33 percent will “resist” to multiple in-
terventions, including non-pharmacological therapies [2].  
Increasing the burden associated with MDD, its high 
prevalence: World Health Organization (WHO) estimated 
that 5-10% of the population at any given time is suffering 
from identifiable depression needing psychiatric or psycho-
social intervention, while the life-time risk of developing 
depression is 10-20% in females and slightly less in males 
[3]. 
Prevalence estimates for TRD are available from several 
sources, including large clinical trials [4], 
  large meta-
analyses [5],
 or naturalistic studies [6-8]. For example, in the 
first level of the Sequenced Treatment Alternatives to Re-
lieve Depression (STAR*D) trial, only about 30% of patients 
were in remission following up to 12 weeks of therapy with 
the Selective Serotonin Reuptake Inhibitor (SSRI) citalo-
pram [9]. In addition, 15.8% of patients developed an intol-
erable adverse event, 38.6% moderate-to-severe impairment 
due to an adverse event, 8.6% discontinued treatment due to 
adverse events, and 4% developed a serious adverse event, 
findings that underscore efficacy and tolerability limitations 
of treatment with a typical first-line antidepressant agent. 
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Papakostas and Fava [10] reviewed 163 randomized, 
double-blind, placebo-controlled trials involving the use of 
antidepressants for MDD. Approximately 53.4% of patients 
responded following treatment with an antidepressant, com-
pared to 36.6% of patients who responded following the ad-
ministration of a placebo pill. Corey-Lisle and colleagues 
[11] reported that approximately 22% of patients who re-
ceived treatment for depression by their primary-care physi-
cians remitted following 6 months of treatment, 32% were 
partial responders, while 45% were non-responders. Simi-
larly, Rush and colleagues [8] reported an 11% remission 
rate and 26.3% response rate among depressed outpatients 
following 12 months of treatment of depression in one of 
several public-sector community clinics. Petersen and col-
leagues [6] report a 50.4% remission rate among outpatients 
with MDD enrolled in 1 of 2 hospital-based, academically 
affiliated depression specialty clinics (Massachusetts Gen-
eral Hospital, an affiliate of Harvard Medical School and 
Rhode Island Hospital, an affiliate of Brown University) 
following an average of 25.8 weeks of treatment. Finally, it 
is also worth noting that while partial or non-response are 
common, residual symptoms among remitters are also highly 
prevalent [12, 13], being usually associated with poorer psy-
chosocial functioning [14] as well as an increased relapse 
rates [15], higher suicidal ideation and attempts, higher 
number of lifetime hospitalizations, more frequent healthcare 
resources utilization, general practitioner consultation, job 
loss and social retirement [16]. 
ISSUES IN DEFINING TRD: A CLINICAL CONTRO-
VERSY “RESISTANT TO REVISION” 
Attempts at overcoming treatment resistance in major 
depression begin with the clinical controversies in defining 
it.  
Currently, there are no universally accepted operational 
definitions of TRD.   
Since more effective treatment approaches are needed for 
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this narrative review is to assess current major definitions of 
TRD and to briefly discuss its putative bipolar diathesis for 
some of the affected patients. 
Actual definition and clinical classification of TRD rep-
resent debated issues: while some literature evidences tend to 
progressively suggest to revise its current nosology, others 
tend to be more conservative, actually making TRD a “resis-
tant clinical controversy”. 
According to research practice, a lack of response (not 
necessarily TRD per se) is usually defined by “failure to re-
duce of at least 50% in the Hamilton depression (HAM-D) 
[17] total score” or as “failure in reducing below a specific 
cut-off” while less objective TRD clinical definitions include 
“failure in symptoms resolution” or the more accepted “fail-
ure to respond to 2 or more adequate antidepressant trials” 
[18].  
The definition of an adequate treatment trial of antide-
pressant medication varied widely over the years, as the cor-
responding definitions of treatment resistance did. In actual-
ity, TRD patients present with histories of varying degrees of 
treatment adequacy. A high proportion of cases referred to 
university settings specifically for evaluation and treatment 
of "refractory" depressions have not received even a single 
adequate anti-depressant trial [19]. 
Clinical controversies related to TRD refer not only to its 
definition but also to the way this latter is conceived: the 
“adequacy” of a trial as well the definition of “non response” 
seem to be misleading concepts. 
There are 3 major treatment-resistance classification sys-
tems: a 5-stages classification (stages get up depending on 
the number of previously failed adequate trials, with fifth 
one proposing bi-temporal Electroconvulsive Therapy - 
ECT), the National Institute for Clinical Excellence (NICE) 
guidelines (providing a short algorithm) and the multi-level 
structured Massachusetts General Hospital (MGH) criteria 
[20]. 
About the “adequacy” of a trial, there is no absolutely 
“correct” dosage for a specific antidepressant, since dosage 
requirements vary depending on factors such as age, weight, 
general health, concomitant medication usage, and tolerance 
of a particular medication. Confirmation of treatment ade-
quacy by more objective means (e.g., serial plasma drug lev-
els) is not the rule in clinical practice, and valid plasma 
level–response relationships are limited to only a subgroup 
of the Tricyclic Antidepressants (TCAs) and lithium salts. 
Conventionally, adequate trials should last at least for 8-
weeks, considering full antidepressant doses (e.g. 20-
60mg/day for the SSRI fluoxetine or 150-300mg/day for the 
TCA clomipramine) when needed. Yet, 8-weeks is just the 
average RCTs follow-up, with clinical practice often requir-
ing more prolonged exposure time. Remission usually takes 
up to 6 months of MDD antidepressant therapy, while recov-
ery – with substantial symptoms resolution – usually requires 
at least a 12 months follow-up. Remarkably, most of antide-
pressant medications have a lag-phase of at least 3-4 weeks 
prior exhibiting any substantial clinical response, thus mak-
ing hyper-dosing a rational strategy if response observed by 
weeks 5 or 6 is insufficient, while a too praecox pharmacol-
ogical switch should be avoided in all the cases [21]. 
With respect to psychotherapy, adequacy of treatment 
may depend on the number of sessions, the expertise of the 
practitioner, the therapist's adherence to a particular form of 
therapy, and/or the interaction of the patient–therapist dyad 
[22]. ECT may be gauged by the total number of treatments, 
the use of bilateral electrode placement, and the verification 
of seizure time by electroencephalographic monitoring. 
Therefore, the terms "relative" and "absolute" treatment re-
sistance may best describe lesser and greater degrees of cer-
tainty about the adequacy of a specific treatment trial [19, 
23]. 
Similarly substantial variability exists as to the definition 
of an acceptable treatment response.  
The most common response criteria in clinical trials are a 
rating of at least "much improved" on the Clinical Global 
Impressions (CGI) scale, a pre-specified level of improve-
ment on a depression symptom rating scale (e.g., >50% re-
duction in Hamilton Depression Rating Scale scores), a final 
absolute score on a symptom measure, or some combination 
of the above. Both the use of composite outcome criteria and 
documentation of persistent improvement (e.g., for 2 weeks 
or longer) may improve reliability and validity of classifica-
tion [24]. 
At least a 50% reduction in depressive symptom severity 
generally corresponds to the clinician's global clinical im-
pression of a moderate level of improvement [2]. However, 
some patients meeting this commonly used response defini-
tion continue to have considerable residual symptomatology. 
Residual symptoms convey a higher risk of relapse during 
continuation treatment and likely contribute to suboptimal 
restoration of vocational or interpersonal functioning. There-
fore, complete symptom remission is the desired outcome of 
acute treatment. The term remission describes a response in 
which a formerly depressed person's level of residual symp-
tomatology is essentially indistinguishable from someone 
who has never been depressed. With respect to standardized 
scales, a score of 6 or less on the 17-item Hamilton Rating 
Scale for Depression is often used to define a remission [17]. 
As for response, non-response quantification may vary 
(HAM-D17>75%=remission; 50%-74%=response; 25%-
49%=partial response; <25%=non-response), with “treat-
ment-non-response” being also defined as poor response to a 
single adequate antidepressant trial and “treatment-resistant 
depression” and “chronic-resistant depression” if resistance 
lasts for at least 12 months despite 2 or more adequate anti-
depressant trials (including augmentation strategies). 
As further confounding variable, the fact that TRD itself 
sometimes receives different appellations (e.g. “treatment-
refractory” or “therapy-resistant” depression) as no univocal 
definition of the “adequacy” of an antidepressant trial does 
exist, making a desirable revision of current TRD nosology a 
difficult, “resistant”, process. 
CLINICAL MANAGEMENT 
Overcoming TRD nosological boundaries require a care-
ful evaluation of the associated clinical features. 
First step should be an appropriate anamnesis, eventually 
integrating validated instruments as the Antidepressant 
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The recognition of depression subtypes (particularly mel-
ancholic, psychotic, atypical, and seasonal) is an important 
element in the evaluation and management of TRD because 
individuals with different subtypes of depression may re-
spond in somewhat different ways to the available therapies, 
or eventually predict a soft bipolar diathesis (e.g. in case of 
seasonal or atypical features). Additionally, resistance to 
treatment may also be related to differential diagnosis mis-
takes as misdiagnosis of a unipolar MDD in patients with 
declared (full-threshold) or undeclared (sub-threshold) BD.  
Patients with BD present in the depressive phase 2 to 3 
times more often than they do in the manic state and it is 
estimated that BD I is undetected in 35% to 45% of patients 
[27].  It is important to evaluate patients with TRD specifi-
cally for a history of manic or hypomanic episodes to rule 
out bipolar spectrum disorders since depressive episodes 
may be the (only) clinical presentation of Bipolar Disorders 
(BDs) for many years [28]. 
Compliance is also a sensitive issue, while a delayed 
“adequate” treatment should become ineffective if too much 
retarded: only 60% of persons with depression are treated for 
the disorder [2]. 
An appropriate evaluation of psychiatric and medical co-
morbidities as well a careful acknowledgement of current 
Major Depressive Episode (MDE) features is mandatory.  
As mentioned, many of TRD cases show-up with psy-
chotic or atypical features, often requiring more personalized 
therapies [29, 30]; for example, treating with SSRIs instead 
of Mono-Amino-Oxidase Inhibitors (MAO-I) or TCAs a 
MDE with atypical features may lead to “pseudo-resistance” 
instead of a true “resistance” phenomenon [31]. 
Concerning axis-I psychiatric co-morbidities, Souery et 
al. (1999) reported up to 3.2% (p<0.001) Panic Disorders, 
Social Phobia 2.1%; (p<0.008), other anxiety disorders 2.6% 
(p<0.001) and axis-II DSM-IV-defined Personality Disorders 
1.7% (p<0.049). Remarkably, early age of onset (<18 years) 
1.7% (p<0.009) and current DSM-IV-defined melancholic 
features 1.5% (p<0.018) were a frequent TRD association 
[20]. Also, most TRD cases have multiple co-morbidities 
and this further increases the burden load, reducing the 
chance of a substantial inter-episodic depressive symptoms 
resolution, therefore increasing the risk for relapse [15]. One 
of the most important set of comorbidities that contributes to 
inadequate treatment response in MDD and other disorders is 
substance (including alcohol) use disorders  and it may be 
carefully considered too when treatment resistance arises in 
MDD patients since this may require specific treatment ap-
proaches [32] and eventually be in favor of  a bipolar diathe-
sis [33]. 
TRD comorbid psychiatric disorders are often missed or 
are sub-optimally treated, and they can confound both the 
evaluation and the management of depression.  
TRD-associated biological factors include a reduction in 
frontal cortex and hippocampal volumes, increase in ven-
tricular volume and amygdala hyperactivity with poor inhibi-
tion by prefrontal-cortex, contributing in making most TRD 
patients hypersensitive to environmental stressors [34]. 
Nonetheless, currently proposed biomarkers for TRD still 
require further evidences as false positives cases could occur 
[35]. 
Frequent TRD medical co-morbidities include infective 
diseases (e.g. HIV and borna virus) and endocrine disorders 
as hypothyroidism or HPA-axis imbalances (up to 50% of 
TRD cases present a non-suppression with the dexametha-
sone test due to HPA hyperactivity) [36]. Yet, a major medi-
cal comorbidities for most TRD cases is represented by car-
diovascular disease and diabetes [37, 38]. 
The implication for treatment is to address these condi-
tions simultaneously, if possible, to avoid consolidating 
treatment resistance [28]. 
THE NEED FOR THERAPEUTIC MANAGEMENT 
AND NOSOLOGICAL REVISIONS 
What if TRD persists despite repetitive “adequate” trials 
and accurate considerations of the potential confounding or 
concomitant factors? 
To date, the STAR*D study represents the broadest, 
multi-centric clinical trial ever conducted on MDD assess-
ment [39]. STAR*D lasted for 7 years (Oct 1999-Sept 2006) 
involving both primary care and psychiatric facilities and 
adopting minimum exclusion criteria (“real world”), with 
“remission” as primary outcome instead of “response”. Re-
markably, 2876 patients (4041 enrolled) had at least one 
axis-I co-morbidity at baseline. Unfortunately, despite a 
multi-level algorithm including switches and augmentation 
strategies with different “antidepressant” classes, lithium, 
thyroid hormones and Cognitive Behavioral Therapy (CBT), 
remission rates were almost equivalent for stages I vs. II 
(32.9% vs. 30.6%) and stages III vs. IV (final), (13.6% vs. 
14.7%); authors concluded that no specific antidepressant 
treatment was superior to any other one, with CBT role re-
maining a debated issue [40].  
While popular clinical augmentation or switch strategies 
for TRD include a broad number of compounds (e.g., thyroid 
hormones, estrogen, lithium, pindolol, atypical antipsychot-
ics, stimulants, inositol, Omega-3 fatty acids, DA-agonists, 
herbal supplements, lamotrigine, etc…) most of them are not 
accounted in “official” TRD guidelines [41]. Also, meta-
analyses data tend to suggest the switch strategy versus the 
augmentation one, with lithium and atypical antipsychotic 
medication as more favored choice [5, 42, 43]. 
Remarkably, lithium and atypical antipsychotics use is 
much more consolidated for bipolar disorders rather than 
unipolar depression. Should be this an ex-adiuvantibus ther-
apy? Also, it is interesting to observe how a considerable 
number of TRD cases show-up with atypical-MDEs or have 
an earlier age of onset compared non-resistant MDDs?  
Sharma  et al. (2005) tried to answer at some of these 
questions investigating 69 patients diagnosed with treatment 
resistant-MDD (“failure to respond to 2 or more adequate 
clinical trials”) at a local mood clinic; when patients were re-
tested using the Structured Clinical Interview for Axis-I dis-
orders (SCID-I) [44] 35% of them were diagnosed as bipo-
lar. The whole sample, was re-tested 1 year later, showing 
41% MDD, 3% BP-I, 43% BP-II, 13% bipolar-NOS. Inter-
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in Clinical Global Impression (CGI) [45] total score when 
switched from antidepressants to mood-stabilizers [46]. 
Indeed, most “false unipolar” [47] TRD cases presented a 
rapid pop-up on antidepressant, frequent motor agitation, 
somatic symptoms and fatigue and a history of polyphar-
macy, which may be accounted as a potential iatrogenic phe-
nomenon for mixed  states and cyclicity among those with a 
supposed bipolar diathesis [48]. 
Further evidences suggesting that some TRD-MDD pa-
tients may have (or acquire) a bipolar diathesis, have been 
also provided by the French national naturalistic “EPIDEP” 
study, which major outcomes included the evaluation of bi-
polar patients using also temperamental instruments (as the 
Temperament Evaluation of the Memphis, Pisa, Paris, and 
San Diego Auto-questionnaire – TEMPS-A) [49]. Cy-
clothymic-sensitive and Depressive temperaments, along 
with motor agitation, greater severity of current depressive 
episode, scored significantly higher among those with BP-
TRD [50]. 
The adoption of less restrictive diagnostic criteria (e.g. 2 
days of hypomania vs. the arbitrary DSM-IV 4 days duration 
one) and the use of sensitive (yet acceptable in sensitivity) 
instruments (e.g. Hypomania Check-List 32-items – HCL-
32) [51] may lead to a prompter recognition of sub-threshold 
“resistance” clusters (e.g. “depressive mixed states” – MDE 
+ 2 hypomanic features) [52] following a bipolar diathesis. 
SHOULD SOME TRD CASES FOLLOW A BIPOLAR 
DIATHESIS OR SHOULD THE TRD NOSOLOGY 
BEEN REVISED? 
While no data support the evidence that all TRD cases 
should follow a bipolar diathesis, neither they support the 
opposite.  
It is interesting to observe how most recent evidences 
tend to suggest a bipolar diathesis in a subgroup of DSM-IV-
defined unipolar depressed patients and how significantly 
should the clinical outcome be influenced by different thera-
peutic implications (as pointed out by preliminary System-
atic Treatment Enhancement Program for Bipolar Disorder – 
STEP-BD evidences) [53]. 
Finally, when TRD lasts for a very long time (despite re-
petitive “adequate” trials), it should be prudent to promptly 
revise diagnosis and/or therapeutic choices.  
In fact, prolonged antidepressant treatments may induce 
bipolar phenomena as rapid cyclicity and mixed states as 
well as antidepressant-resistance in some patients and their 
over-prescription should therefore be avoided [54], prefer-
ring lithium and atypical antipsychotics, as indicated by the 
BP-TRD algorhythm recently proposed by Pacchiarotti et al. 
[55]. 
Also, while a bipolar hypothesis for some TRD cases is 
definitely not a novel approach, it appears to become a 
gradually more popular remark, especially considering that 
further insights are progressively acquired about a potential 
bipolar diathesis for some of the features sometimes associ-
ated with TRD too: just to mention one, a history of sub-
stance abuse is today almost widely accepted as a strong 
bipolar feature. 
In conclusion, directions for future research on TRD 
shouldn’t apart from a substantial revision of the way TRD 
itself is defined. Adopting widely accepted criteria for the 
“adequacy” of a trial as well for the concept of “resistance” 
is mandatory in order to allow researchers to give rise to a 
hoped international collaborative group. Specifically, more 
attention should be placed on a plausible bipolar diathesis for 
some of the TRD cases as a progressively greater number of 
latest literature evidences tend to support this view. 
Otherwise, till a consistent revision of current bounda-
ries of TRD nosology will be performed, we’ll have no op-
portunity to fully overcome the resistance phenomenon. 
CORE ABBREVIATIONS 
TRD: as Treatment Resistant Depression; MDD: as Ma-
jor Depressive Disorder; BP: as Bipolar Disorder. 
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